Thioguanine Interactions

Brand names: Tabloid

Route: Oral

Contraindications

CONTRAINDICATIONS Thioguanine should not be used in patients whose disease has demonstrated prior resistance to this drug. In animals and humans, there is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.

Pregnancy & Breastfeeding

Pregnancy Drugs such as thioguanine are potential mutagens and teratogens. Thioguanine may cause fetal harm when administered to a pregnant woman. Thioguanine has been shown to be teratogenic in rats when given in doses 5 times the human dose. When given to the rat on the 4th and 5th days of gestation, 13% of surviving placentas did not contain fetuses, and 19% of offspring were malformed or stunted. The malformations noted included generalized edema, cranial defects, and general skeletal hypoplasia, hydrocephalus, ventral hernia, situs inversus, and incomplete development of the limbs. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Pregnancy Teratogenic Effects: See WARNINGS section.

5 interactions on record

Additive myelosuppression and hepatotoxicity risk; portal hypertension and esophageal varices observed with long-term combination therapy. Long-term continuous therapy should be used with caution.

Source: NLP:busulfan

Complete cross-resistance between mercaptopurine and thioguanine; concurrent use not recommended.

Source: NLP:thioguanine

Inhibits TPMT enzyme; should be administered with caution to patients receiving concurrent thioguanine therapy.

Source: NLP:thioguanine

Inhibits TPMT enzyme; should be administered with caution to patients receiving concurrent thioguanine therapy.

Source: NLP:thioguanine

Inhibits TPMT enzyme; should be administered with caution to patients receiving concurrent thioguanine therapy.

Source: NLP:thioguanine